Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$126B
P/E ratio
~35×
Div yield
~0.9%
Revenue (FY25)
~$24.6B
Free cash flow
~$5.3B
Profit margin
~15%
Rev. growth
~+3%
Segments
3 (Bio/LS/Dx)
In plain English
Danaher sits upstream of nearly every modern medicine. Through Cytiva and Pall it sells the bioreactors, filters and chromatography resins drugmakers use to grow and purify biologic medicines; through Cepheid, Beckman Coulter and Leica it runs the diagnostic tests that tell doctors what's wrong; and through SCIEX, IDT and Aldevron it arms the labs inventing the next therapy. A serial acquirer run on the Danaher Business System, it bought GE's biopharma arm for ~$21B, spun off its industrial and water businesses (Fortive, Veralto), and in 2026 bought patient-monitoring maker Masimo for ~$9.9B.
In simple terms
Danaher sits one step upstream of medicine
You rarely see Danaher's name, yet it touches almost every modern treatment. Its Cytiva and Pall hardware grows and purifies the biologic drugs you take; its Cepheid, Beckman and Masimo systems run the tests and monitors that tell doctors what's happening inside you. Danaher sells the picks and shovels of the health economy.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.